Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Type 1 Diabetes Grand Challenge invests £5 million to kick off the race towards a cure
Dr Victoria Salem at Imperial College London
We’re excited to reveal the first research projects funded by the Type 1 Diabetes Grand Challenge, our partnership with the Steve Morgan Foundation and Diabetes UK.
£5 million will support a trio of exceptional scientists to develop new and improved treatments for type 1 diabetes and marks the start of a £50 million programme of research, made possible by the Steve Morgan Foundation’s landmark investment.
The funding goes to scientists in different corners of the UK, who will each solve different problems to help propel us towards a cure.
Dr James Cantley, at the University of Dundee, will develop new drugs to help people with type 1 diabetes grow back their own beta cells inside their pancreas. This approach could avoid problems with the immune system rejecting transplanted ‘foreign’ donor or lab-made beta cells and allow the pancreas to produce its own insulin again.
Dr Cantley said, “Regenerating beta cells in the pancreas has the potential to revolutionise the treatment of type 1 diabetes, by replacing cells destroyed by the immune attack, and ultimately leading to stable blood sugar levels and a life free from insulin injections.”
Dr Victoria Salem, at Imperial College London, will use state-of-the-art 3D bioprinting to ‘print’ a device that can be implanted into people with type 1 diabetes to deliver a new supply of beta cells.
The device will act as a barrier and protect the beta cells sitting inside, by blocking attacking immune cells, while still letting in vital nutrients they need to survive.
Dr Salem said, “The dream for a cell cased cure for type 1 diabetes is now tantalisingly close – I’m so excited and honoured to be a part of this journey.”
Professor Sarah Richardson, at the University of Exeter, will probe how and why a person’s immune system destroys their own beta cells and how this process may differ between people with type 1 diabetes. She’ll also study how beta cells can fight back against the immune attack.
With this knowledge, scientists could develop an armoury of new treatments that target different lines of the immune system’s attack.
Professor Richardson said, “Ultimately, this will help us tailor existing and emerging therapies to the individual, maximising the benefits for people with type 1 diabetes.”
Read more about the Grand Challenge researchers’ plans on the Type 1 Diabetes Grand Challenge website.
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.